Market revenue in 2023 | USD 28.1 million |
Market revenue in 2030 | USD 48.3 million |
Growth rate | 8% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.7% in 2024. Horizon Databook has segmented the South Africa in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
South African government is making multiple efforts to build research capabilities by increasing the pool of clinical research professionals in South Africa, such as promoting partnerships among pharmaceutical companies, medical device industry, & Department of Health and collaborating with various Stakeholders. However, disinvestment in publicly funded programs and absence of discounts for research tests are some factors likely to indirectly impede the in vivo CRO market growth in the country.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account